GlaxoSmithKline Research & Development, Infectious Diseases Therapeutic Area Unit, Five Moore Drive, Research Triangle Park, NC 27709, United States.
GlaxoSmithKline Research & Development, Infectious Diseases Therapeutic Area Unit, Five Moore Drive, Research Triangle Park, NC 27709, United States.
Eur J Med Chem. 2014 Aug 18;83:609-16. doi: 10.1016/j.ejmech.2014.06.061. Epub 2014 Jun 28.
Using a structure based pharmacophore design, a weak inhibitor of RNase H, identified from a small library of two metal binding HIV-1 integrase inhibitors, was optimized for potency and physicochemical properties. This manuscript describes the SAR and in vivo DMPK for the pyridopyrimidinone class of inhibitors.
采用基于结构的药效团设计,从小型的两个金属结合 HIV-1 整合酶抑制剂文库中鉴定出的 RNase H 的弱抑制剂,对其效力和理化性质进行了优化。本文描述了吡啶并嘧啶酮类抑制剂的 SAR 和体内 DMPK 研究结果。